查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1629907

全球預充式注射器市場 - 2025-2033

Global Pre-Filled Syringes Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 179 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2023年，全球預充式注射器市場規模達865,606萬美元，預估至2033年將達到30,04262萬美元，2025-2033年預測期間複合年成長率為15.5%。

預充式注射器是即用型醫療器械，含有預先計量的藥物或疫苗劑量。這些注射器預先安裝了特定量的藥物，方便醫療保健專業人員和患者使用。預充式注射器通常由注射器筒、柱塞和針頭或針頭護罩組成。有些預充式注射器具有安全功能，例如針頭護罩或可伸縮針頭，以提高使用和處置過程中的安全性。與某些傳統形式的藥物包裝相比，預充式注射器通常具有更長的保存期限，因為它們可以保護藥物免受環境因素的影響。

自我照護干預措施的興起在推動醫療保健市場對預充式注射器的需求方面發揮了重要作用。隨著人們在健康管理方面發揮更積極的作用，自我用藥變得越來越普遍。例如，根據美國國立衛生研究院 (NIH) 進行的研究，共有 234 名患者完成了問卷調查。有一半（50%）的患者願意自行用藥。然而，只有 37% 的患者更喜歡自行用藥，而不是護理師主導的用藥。預充式注射器提供了一種使用者友好的解決方案，無需進行複雜的劑量測量，並使個人更容易自行給藥。此外，根據哈佛大學的數據，全球每年使用 70 億支預充式注射器。

市場動態：

驅動程式和限制

自我管理日益普及

自我管理的日益普及極大地推動了預充式注射器市場的成長，預計將在預測期內推動該市場的成長。自我給藥允許患者在舒適的家中注射藥物，這對於糖尿病、類風濕性關節炎和多發性硬化症等慢性疾病尤其重要。這種便利性減少了頻繁去醫院的需要，從而為患者和醫療保健提供者節省了時間和成本。

例如，根據美國國立衛生研究院 (NIH) 進行的研究，大多數 (62%) 糖尿病研究患者對自行注射胰島素持正面態度。儘管177例（72.2%）的研究患者中大多數人自己注射過胰島素，但只有120例（49.0%）的患者在45度適當注射胰島素。

根據國際糖尿病聯盟估計，到2035年，糖尿病患者將達到5.92億。糖尿病發生率的上升增加了對自行注射胰島素的需求，進而增加了對預充式注射器的需求。

家庭醫療保健服務的成長與自我照護趨勢密切相關。預充式注射器非常適合家庭醫療保健模式，使患者無需頻繁去醫院或診所即可接受必要的治療。遠距醫療和遠端監控技術的越來越多的使用支持自我護理干預。可以在虛擬諮詢期間開出預裝注射器，醫療保健提供者可以遠端監控患者的進展，並根據需要提供治療計劃的指導和調整。

此外，根據世界衛生組織估計，世界上五分之一的人口目前生活在人道危機中​​，衛生系統在提供基本服務方面面臨挑戰。自我保健干預措施是支持個人、家庭和社區在有或沒有衛生工作者支持的情況下促進健康、預防疾病、維持健康以及應對疾病和殘疾的能力的工具。

藥物容量有限

由於限制其實用性的一些挑戰，預充式注射器有限的藥物容量預計將阻礙市場的成長，特別是對於複雜和大容量的藥物。與小瓶和其他包裝形式相比，預充式注射器的藥物容量通常較小。這限制了他們使用具有特定劑量要求的藥物。許多預充式注射器設計用於單劑量應用，通常將總體積限制為 1 至 2 mL。

例如，根據糖尿病期刊組織的資料，胰島素注射器有不同尺寸，包括 0.3、0.5 和 1.0 mL 尺寸，分別可容納 30、50 和 100 單位的胰島素。由於注射器容量的限制，預充式胰島素注射器的最大劑量限制在 1.0 mL 左右。這對於需要較大劑量的藥物來說可能不夠。

許多生物製品和高濃度藥物需要更大的體積才能有效治療，但由於容量有限，預充式注射器並不總是合適。對於腫瘤學中使用的藥物來說，這項挑戰尤其明顯，因為需要高濃度和高劑量來維持療效。例如，市面上大多數預充式注射器的容量最多為 2 mL，這可能不足以容納單株抗體和高濃度生物製劑等藥物。

目錄

第1章：市場介紹和範圍

  • 報告的目標
  • 報告範圍和定義
  • 報告範圍

第 2 章：高階主管見解與要點

  • 市場亮點和戰略要點
  • 主要趨勢和未來預測
  • 按產品分類
  • 按材料分類
  • 設計片段
  • 按應用程式片段
  • 最終使用者的片段
  • 按地區分類的片段

第 3 章：動力學

  • 影響因素
    • 促進要素
      • 糖尿病盛行率上升
      • 不斷進步的技術
    • 限制
      • 資料隱私問題
    • 機會
    • 影響分析

第 4 章：策略洞察與產業展望

  • 市場領導者和先驅
    • 新興先鋒和傑出參與者
    • 擁有最大銷售品牌的知名領導者
    • 擁有成熟產品的市場領導者
  • 新興新創企業和關鍵創新者
  • CXO 觀點
  • 最新進展和突破
  • 案例研究/正在進行的研究
  • 監管和報銷情況
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 波特五力分析
  • 供應鏈分析
  • 專利分析
  • SWOT分析
  • 未滿足的需求和差距
  • 市場進入和擴張的推薦策略
  • 情境分析：最佳情況、基本情況和最壞情況預測
  • 定價分析和價格動態

第 5 章：預充式注射器市場，依產品

  • 無針預充式注射器
  • 附針預灌封注射器

第 6 章：預填充注射器市場（依材料）

  • 玻璃預灌封注射器
  • 塑膠預灌封注射器

第 7 章：預充式注射器市場的設計

  • 單室 PFS
  • 雙室 PFS

第 8 章：預充式注射器市場（按應用）

  • 糖尿病
  • 類風濕關節炎
  • 眼科
  • 過敏反應
  • 其他

第 9 章：預填充注射器市場（依最終使用者）

  • 醫院和診所
  • 門診手術中心
  • 其他

第 10 章：預填充注射器市場，按區域市場分析和成長機會

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲

第 11 章：競爭格局與市場定位

  • 競爭概況和主要市場參與者
  • 市佔率分析與定位矩陣
  • 策略夥伴關係、併購
  • 產品組合和創新的主要發展
  • 公司基準化分析

第 12 章：公司簡介

  • Becton, Dickinson, and Company
    • 公司概況
    • 產品組合和描述
    • 財務概覽
    • 主要進展
    • SWOT分析
  • Gerresheimer AG
  • Schott AG
  • Stevanato Group SpA
  • Terumo Corporation
  • Sanofi SA
  • Hikma Pharmaceuticals PLC
  • MedXL Inc.
  • West Pharmaceutical Services, Inc.
  • Cardinal Health

第 13 章：假設與研究方法

  • 資料收集方法
  • 數據三角測量
  • 預測技術
  • 數據驗證和確認

第 14 章：附錄

簡介目錄
Product Code: MD692

The global pre-filled syringes market reached US$ 8656.06 million in 2023 and is expected to reach US$ 30042.62 million by 2033, growing at a CAGR of 15.5% during the forecast period 2025-2033.

Pre-filled syringes are ready-to-use medical devices containing a pre-measured medication or vaccine dose. These syringes come pre-loaded with a specific amount of a drug, making them convenient for healthcare professionals and patients. The pre-filled syringe typically consists of a syringe barrel, a plunger, and a needle or a needle shield. Some pre-filled syringes come with safety features, such as needle shields or retractable needles, to enhance safety during use and disposal. Pre-filled syringes often have a longer shelf life compared to some traditional forms of medication packaging, as they can protect the drug from environmental factors.

The rise of self-care interventions has played a significant role in driving the demand for pre-filled syringes in the healthcare market. Self-administration of medications is becoming increasingly common as people take a more active role in managing their health. For instance, according to the Study conducted by the National Institute of Health (NIH), in total, 234 patients completed the questionnaire. Half (50%) of the patients were willing to self-administer medication. However, only 37% of patients preferred self-administration of medication over nurse-led medication administration. Pre-filled syringes offer a user-friendly solution, eliminating the need for complex dosage measurements and making it easier for individuals to self-administer their medications. Additionally, according to Harvard University, 7 billion prefilled syringes are used annually around the world.

Market Dynamics: Drivers & Restraints

Rising popularity of self-administration

The rising popularity of self-administration is significantly driving the growth of the pre-filled syringes market and is expected to drive the market over the forecast period. Self-administration allows patients to inject medications in the comfort of their homes, which is particularly important for chronic conditions such as diabetes, rheumatoid arthritis and multiple sclerosis. This convenience reduces the need for frequent hospital visits, thus saving time and costs for both patients and healthcare providers.

For instance, according to the study conducted by the National Institute of Health (NIH), the majority (62%) of the diabetes study patients had a favorable attitude toward insulin self-administration. Although the majority of 177(72.2%) of the study patients have administered insulin themselves, only 120(49.0%) of the patients injected insulin appropriately at 45 degrees.

According to the International Diabetes Federation estimated that diabetes reach 592 million in the year 2035. Similarly, there were more than 1.8 million diabetes patients in Ethiopia with a national prevalence of 4.36% among the adult population. This rising diabetes increases the demand for insulin self-administration, which in turn increases the demand for prefilled syringes.

The growth of home healthcare services is closely tied to the self-care trend. Pre-filled syringes fit well within the home healthcare model, allowing patients to receive necessary treatments without the need for frequent hospital or clinic visits. The increasing use of telemedicine and remote monitoring technologies supports self-care interventions. Pre-filled syringes can be prescribed during virtual consultations, and healthcare providers can remotely monitor patients' progress, offering guidance and adjustments to treatment plans as needed.

Additionally, according to WHO, estimated that 1 in 5 of the world's population are now living in humanitarian crises, in which health systems are challenged to deliver essential services. Self-care interventions are tools that support the ability of individuals, families and communities to promote health, prevent disease, maintain health, and cope with illness and disability with or without the support of a health worker.

Limited drug capacity

The limited drug capacity of pre-filled syringes is expected to hamper the growth of the market due to several challenges that restrict their utility, especially for complex and large-volume drugs. Pre-filled syringes typically have a smaller drug capacity compared to vials and other packaging formats. This restricts their use of medications with specific dosage requirements. Many pre-filled syringes are designed for single-dose applications, often limiting the total volume to 1 to 2 mL.

For instance, according to the Diabetes Journals Organization, insulin syringes come in different sizes, including 0.3, 0.5 and 1.0 mL sizes that hold up to 30, 50, and 100 units of insulin, respectively. Insulin pre-filled syringes are limited to a maximum dose of around 1.0 mL due to syringe capacity constraints. This may not be sufficient for medications requiring larger doses.

Many biologics and high-concentration drugs require larger volumes for effective treatment, but pre-filled syringes are not always suitable due to limited capacity. The challenge is particularly pronounced with drugs used in oncology, where high concentrations and volumes are needed to maintain efficacy. For instance, the majority of pre-filled syringes on the market can hold up to 2 mL, which might not be sufficient for drugs like monoclonal antibodies and high-concentration biologics.

Segment Analysis

The global pre-filled syringes market is segmented based on product, material, design, application, end-user and region.

Product Type:

The needled prefilled syringes segment is expected to dominate the pre-filled syringes market share

Needled pre-filled syringes are widely used for a range of applications, including insulin administration, vaccines and biologic therapies. Insulin and diabetes management are prime examples, where pre-filled syringes equipped with needles provide a reliable and convenient method for daily self-administration. Needled pre-filled syringes are preferred for their ability to deliver drugs directly into the bloodstream, ensuring effective therapeutic outcomes. The presence of a needle allows for precise dosing, which is crucial for biologics and therapies requiring targeted delivery.

For instance, in September 2024, BD (Becton, Dickinson and Company) released the BD Neopak XtraFlow Glass Prefillable Syringe and the latest capacity expansion of the BD Neopak Glass Prefillable Syringe platform to serve the growing market for biologic therapies. This solution features an 8-millimeter needle length and thinner wall cannula to optimize subcutaneous delivery of higher viscosity drug profiles by reducing the injection force and time required for a fixed solution viscosity. The BD Neopak Glass Prefillable Syringe platform is designed to address key development needs for biologic drugs.

Advanced safety mechanisms integrated into needled pre-filled syringes improve their safety profile. These features have become essential in healthcare settings, especially for hospital administrations, and for patient safety. For instance, in August 2024, Schreiner MediPharm introduced Needle-Trap Secu, a protection label with a newly integrated seal function that enhances sustainability and cost efficiency in the storage, transportation and disposal of prefilled syringes. Its compact design technology effectively protects against needlestick injuries while saving space and resources.

Geographical Analysis

North America is expected to hold a significant position in the pre-filled syringes market share

There is a growing trend towards self-administration in North America especially in the United States, driven by the convenience it offers to patients and caregivers. Self-injection pens and needled pre-filled syringes are widely used for managing chronic conditions like diabetes, rheumatoid arthritis, and multiple sclerosis. For instance, the National Institute of Health reports indicate that in the United States, approximately 40% of the population self-medicates, this further boosts the demand for prefilled syringes in the region.

North America is a major market for biologics and biosimilars, which are primarily delivered using pre-filled syringes. The growing prevalence of chronic diseases and the increasing adoption of biologics for treatment have driven the demand for pre-filled syringes in the region. For instance, according to the Pharmaceutical Research and Manufacturers of America, as of the end of 2022, 40 biosimilars have been approved and there are 27 biosimilars on the market in the U.S. competing against ten brand biologics with several more scheduled to launch throughout 2023.

Asia-Pacific is growing at the fastest pace in the Pre-Filled Syringes market

Rapidly improving healthcare infrastructure across countries like China, India, Japan, South Korea, and others in the APAC region is driving the adoption of advanced medical devices like pre-filled syringes. Investments in healthcare facilities, government initiatives to improve access to quality healthcare, and the establishment of specialized hospitals and clinics are boosting the demand for pre-filled syringes. For instance, in China, the government's healthcare reforms have led to increased spending on healthcare infrastructure, which is accelerating the adoption of advanced drug delivery systems such as pre-filled syringes.

For instance, in June 2022, WuXi Biologics launched the GMP operation of its new drug product facility DP5 located in Wuxi, China. The DP5 is the ninth operational drug product facility in the global network of WuXi Biologics. The DP5 facility features an isolator filling line for continuous and steady filling services, which offers multiple volume delivery options for pre-filled syringes (PFS), including 1 mL Long, 1 mL, 2.25 mL and 3 mL, notes WuXi. The maximum filling speed reportedly can reach 400 PFS/min to support 17 million syringes of drug products manufacturing every year.

The rising prevalence of chronic diseases such as diabetes, cardiovascular diseases and cancer in the APAC region is a major driver. These diseases often require long-term treatment regimens, making pre-filled syringes a convenient and preferred method of drug delivery. For instance, China has one of the highest numbers of diabetes patients, currently having 140.9 million people with diabetes, which is set to increase to 174.4 million by 2045., driving the demand for insulin-pre-filled syringes

Competitive Landscape

The major global players in the pre-filled syringes market include Becton, Dickinson, and Company, Gerresheimer AG, Schott AG, Stevanato Group S.p.A., Terumo Corporation, Sanofi S.A., Hikma Pharmaceuticals PLC, MedXL Inc., West Pharmaceutical Services, Inc., Cardinal Health and among others.

Key Developments

  • In September 2024, BD (Becton, Dickinson and Company) announced the commercial release of the BD Neopak XtraFlow Glass Prefillable Syringe and the latest capacity expansion of the BD Neopak Glass Prefillable Syringe platform to serve the growing market for biologic therapies.
  • In March 2024, Biocon Biologics, a subsidiary of Biocon, on Monday officially announced a settlement with Bayer and Regeneron Pharmaceuticals. This agreement allows Biocon Biologics to launch Yesafili, a proposed biosimilar to EYLEA (aflibercept) Injection, in the Canadian market. Under the terms of the company agreement, Biocon Biologics has secured a launch date for Yesafili 2 mg New Drug Submission (NDS) for vials and prefilled syringes, with the launch set up to July 1, 2025.
  • In January 2023, Schreiner MediPharm presented a security label for syringes at Pharmapack Paris in early February. Met with ample interest among eventgoers, the company's Syringe-Closure-Wrap is a multifunctional label for pre-filled syringes that provides a clear first-opening indication, enabling the detection of previous use, tampering or counterfeiting attempts.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global pre-filled syringes market report delivers a detailed analysis with 78 key tables, more than 71 visually impactful figures, and 179 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Product
  • 2.4. Snippet by Material
  • 2.5. Snippet by Design
  • 2.6. Snippet by Application
  • 2.7. Snippet by End-User
  • 2.8. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Prevalence of Diabetes
      • 3.1.1.2. Rising Technological Advancements
    • 3.1.2. Restraints
      • 3.1.2.1. Data Privacy Concerns
    • 3.1.3. Opportunity
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. Emerging Startups and Key Innovators
  • 4.3. CXO Perspectives
  • 4.4. Latest Developments and Breakthroughs
  • 4.5. Case Studies/Ongoing Research
  • 4.6. Regulatory and Reimbursement Landscape
    • 4.6.1. North America
    • 4.6.2. Europe
    • 4.6.3. Asia Pacific
    • 4.6.4. Latin America
    • 4.6.5. Middle East & Africa
  • 4.7. Porter's Five Force Analysis
  • 4.8. Supply Chain Analysis
  • 4.9. Patent Analysis
  • 4.10. SWOT Analysis
  • 4.11. Unmet Needs and Gaps
  • 4.12. Recommended Strategies for Market Entry and Expansion
  • 4.13. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.14. Pricing Analysis and Price Dynamics

5. Pre-Filled Syringes Market, By Product

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 5.1.2. Market Attractiveness Index, By Product
  • 5.2. Needle Free Prefilled Syringes*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Needled Prefilled Syringes

6. Pre-Filled Syringes Market, By Material

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
    • 6.1.2. Market Attractiveness Index, By Material
  • 6.2. Glass Prefilled Syringes*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Plastic Prefilled Syringes

7. Pre-Filled Syringes Market, By Design

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design
    • 7.1.2. Market Attractiveness Index, By Design
  • 7.2. Single Chambered PFS*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Dual Chambered PFS

8. Pre-Filled Syringes Market, By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Diabetes*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Rheumatoid Arthritis
  • 8.4. Ophthalmology
  • 8.5. Anaphylaxis
  • 8.6. Others

9. Pre-Filled Syringes Market, By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Hospitals & Clinics*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Ambulatory Surgical Centers
  • 9.4. Others

10. Pre-Filled Syringes Market, By Regional Market Analysis and Growth Opportunities

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.8.1. U.S.
      • 10.2.8.2. Canada
      • 10.2.8.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.8.1. Germany
      • 10.3.8.2. U.K.
      • 10.3.8.3. France
      • 10.3.8.4. Spain
      • 10.3.8.5. Italy
      • 10.3.8.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.8.1. Brazil
      • 10.4.8.2. Argentina
      • 10.4.8.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.8.1. China
      • 10.5.8.2. India
      • 10.5.8.3. Japan
      • 10.5.8.4. South Korea
      • 10.5.8.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape and Market Positioning

  • 11.1. Competitive Overview and Key Market Players
  • 11.2. Market Share Analysis and Positioning Matrix
  • 11.3. Strategic Partnerships, Mergers & Acquisitions
  • 11.4. Key Developments in Product Portfolios and Innovations
  • 11.5. Company Benchmarking

12. Company Profiles

  • 12.1. Becton, Dickinson, and Company*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
    • 12.1.5. SWOT Analysis
  • 12.2. Gerresheimer AG
  • 12.3. Schott AG
  • 12.4. Stevanato Group S.p.A.
  • 12.5. Terumo Corporation
  • 12.6. Sanofi S.A.
  • 12.7. Hikma Pharmaceuticals PLC
  • 12.8. MedXL Inc.
  • 12.9. West Pharmaceutical Services, Inc.
  • 12.10. Cardinal Health

LIST NOT EXHAUSTIVE

13. Assumption and Research Methodology

  • 13.1. Data Collection Methods
  • 13.2. Data Triangulation
  • 13.3. Forecasting Techniques
  • 13.4. Data Verification and Validation

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us